» Articles » PMID: 38140802

Predictors of Survival in Friedreich's Ataxia: A Prospective Cohort Study

Abstract

Background: Friedreich's ataxia (FA) is a rare multisystemic disorder which can cause premature death.

Objectives: To investigate predictors of survival in FA.

Methods: Within a prospective registry established by the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS; ClinicalTrials.gov identifier NCT02069509) we enrolled genetically confirmed FA patients at 11 tertiary centers and followed them in yearly intervals. We investigated overall survival applying the Kaplan-Meier method, life tables, and log-rank test. We explored prognostic factors applying Cox proportional hazards regression and subsequently built a risk score which was assessed for discrimination and calibration performance.

Results: Between September 2010 and March 2017, we enrolled 631 FA patients. Median age at inclusion was 31 (range, 6-76) years. Until December 2022, 44 patients died and 119 terminated the study for other reasons. The 10-year cumulative survival rate was 87%. In a multivariable analysis, the disability stage (hazard ratio [HR] 1.51, 95% CI 1.08-2.12, P = 0.02), history of arrhythmic disorder (HR 2.93, 95% CI 1.34-6.39, P = 0.007), and diabetes mellitus (HR 2.31, 95% CI 1.05-5.10, P = 0.04) were independent predictors of survival. GAA repeat lengths did not improve the survival model. A risk score built on the previously described factors plus the presence of left ventricular systolic dysfunction at echocardiography enabled identification of four trajectories to prognosticate up to 10-year survival (log-rank test P < 0.001).

Conclusions: Arrhythmias, progressive neurological disability, and diabetes mellitus influence the overall survival in FA. We built a survival prognostic score which identifies patients meriting closer surveillance and who may benefit from early invasive cardiac monitoring and therapy. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Citing Articles

A global perspective on research advances and future challenges in Friedreich ataxia.

Indelicato E, Delatycki M, Farmer J, Franca Jr M, Perlman S, Rai M Nat Rev Neurol. 2025; .

PMID: 40032987 DOI: 10.1038/s41582-025-01065-y.


Safety and efficacy of omaveloxolone v/s placebo for the treatment of Friedreich's ataxia in patients aged more than 16 years: a systematic review.

Umrao A, Pahuja M, Chatterjee N Orphanet J Rare Dis. 2024; 19(1):495.

PMID: 39736600 PMC: 11684145. DOI: 10.1186/s13023-024-03474-6.


Skeletal Muscle Involvement in Friedreich Ataxia.

Indelicato E, Wanschitz J, Loscher W, Boesch S Int J Mol Sci. 2024; 25(18).

PMID: 39337401 PMC: 11432698. DOI: 10.3390/ijms25189915.


New and Emerging Drug and Gene Therapies for Friedreich Ataxia.

Scott V, Delatycki M, Tai G, Corben L CNS Drugs. 2024; 38(10):791-805.

PMID: 39115603 PMC: 11377510. DOI: 10.1007/s40263-024-01113-z.


Repeat length in spinocerebellar ataxia type 4 (SCA4) predicts age at onset and disease severity.

Dalski A, Pauly M, Hanssen H, Hagenah J, Hellenbroich Y, Schmidt C J Neurol. 2024; 271(9):6289-6300.

PMID: 39095619 PMC: 11377680. DOI: 10.1007/s00415-024-12600-0.